BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25252196)

  • 1. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.
    Hambuchen MD; Rüedi-Bettschen D; Williams DK; Hendrickson H; Owens SM
    Vaccine; 2014 Oct; 32(47):6213-9. PubMed ID: 25252196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.
    Hambuchen MD; Rüedi-Bettschen D; Gunnell MG; Hendrickson H; Owens SM
    Hum Vaccin Immunother; 2016 Sep; 12(9):2240-8. PubMed ID: 27163775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
    Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
    MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
    Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
    Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.
    Harris AC; LeSage MG; Shelley D; Perry JL; Pentel PR; Owens SM
    PLoS One; 2015; 10(3):e0118787. PubMed ID: 25742165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
    Gentry WB; Laurenzana EM; Williams DK; West JR; Berg RJ; Terlea T; Owens SM
    Int Immunopharmacol; 2006 Jun; 6(6):968-77. PubMed ID: 16644483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.
    Laurenzana EM; Byrnes-Blake KA; Milesi-Hallé A; Gentry WB; Williams DK; Owens SM
    Drug Metab Dispos; 2003 Nov; 31(11):1320-6. PubMed ID: 14570763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
    Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
    MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.
    Hambuchen MD; Carroll FI; Rüedi-Bettschen D; Hendrickson HP; Hennings LJ; Blough BE; Brieaddy LE; Pidaparthi RR; Owens SM
    J Med Chem; 2015 Jun; 58(11):4665-77. PubMed ID: 25973614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food.
    Rüedi-Bettschen D; Wood SL; Gunnell MG; West CM; Pidaparthi RR; Carroll FI; Blough BE; Owens SM
    Vaccine; 2013 Sep; 31(41):4596-602. PubMed ID: 23906885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.
    White SJ; Hendrickson HP; Atchley WT; Laurenzana EM; Gentry WB; Williams DK; Owens SM
    Drug Metab Dispos; 2014 Aug; 42(8):1285-91. PubMed ID: 24839971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.
    Peterson EC; Laurenzana EM; Atchley WT; Hendrickson HP; Owens SM
    J Pharmacol Exp Ther; 2008 Apr; 325(1):124-33. PubMed ID: 18192498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats.
    Byrnes-Blake KA; Laurenzana EM; Carroll FI; Abraham P; Gentry WB; Landes RD; Owens SM
    Eur J Pharmacol; 2003 Feb; 461(2-3):119-28. PubMed ID: 12586207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats.
    Miller ML; Moreno AY; Aarde SM; Creehan KM; Vandewater SA; Vaillancourt BD; Wright MJ; Janda KD; Taffe MA
    Biol Psychiatry; 2013 Apr; 73(8):721-8. PubMed ID: 23098894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration.
    Gentry WB; Ghafoor AU; Wessinger WD; Laurenzana EM; Hendrickson HP; Owens SM
    Pharmacol Biochem Behav; 2004 Dec; 79(4):751-60. PubMed ID: 15582684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats.
    Laurenzana EM; Hendrickson HP; Carpenter D; Peterson EC; Gentry WB; West M; Che Y; Carroll FI; Owens SM
    Vaccine; 2009 Nov; 27(50):7011-20. PubMed ID: 19800446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of chronic oxytocin treatment during abstinence from methamphetamine self-administration on incubation of craving, reinstatement, and anxiety.
    Everett NA; Baracz SJ; Cornish JL
    Neuropsychopharmacology; 2020 Mar; 45(4):597-605. PubMed ID: 31715618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of an exaggerated locomotor response to a low-dose challenge of methamphetamine.
    Frankel PS; Hoonakker AJ; Danaceau JP; Hanson GR
    Pharmacol Biochem Behav; 2007 Mar; 86(3):511-5. PubMed ID: 17303233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat.
    Rivière GJ; Byrnes KA; Gentry WB; Owens SM
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1220-6. PubMed ID: 10565845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats.
    Byrnes-Blake KA; Laurenzana EM; Landes RD; Gentry WB; Owens SM
    Eur J Pharmacol; 2005 Oct; 521(1-3):86-94. PubMed ID: 16182279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.